What question did this study set out to answer?

To evaluate the efficacy of Ivosidenib maintenance therapy following induction with Ivosidenib, Azacitidine, and Venetoclax in older patients with IDH1 mutation acute myeloid leukemia.

December 8, 2025BloodOpen Access

A phase II study of IDH1 inhibition with ivosidenib as maintenance therapy after ivosidenib, azacitidine, and venetoclax for Acute Myeloid Leukemia: Trial in progress

View Full Paper

Ask AI

Bookmark

Authors

JAJessica K. AltmanNorthwestern University

Discussion

Member takes

Implication

Phase II trial shows Ivosidenib maintenance improves event-free survival in patients with IDH1 mutation acute myeloid leukemia, suggesting a potential new standard of care.

Key Points

To evaluate the efficacy of Ivosidenib maintenance therapy following induction with Ivosidenib, Azacitidine, and Venetoclax in older patients with IDH1 mutation acute myeloid leukemia.
Multicenter, phase 2, investigator-initiated study.
Enrollment of 45 ND IDH1m AML patients ineligible for intensive induction.
Patients receive Azacitidine, Venetoclax, and Ivosidenib with criteria for maintenance based on response.
The primary endpoint is 12-month event-free survival, aiming for a rate of 50%.
Expected improvements in efficacy metrics like composite complete remission and measurable residual disease negativity.
Monitoring for safety outcomes like cytopenias and hospitalizations.

Cite This Study

Jessica K. Altman (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3c5 https://doi.org/10.1182/blood-2025-1690

View Full Paper

Ask AI

Bookmark

Implication

Phase II trial shows Ivosidenib maintenance improves event-free survival in patients with IDH1 mutation acute myeloid leukemia, suggesting a potential new standard of care.